Our Pricing

Wegovy Dosing Schedule for Prescription Weight Loss

Published on: June 03, 2026

Understanding the wegovy dosing schedule uk protocol is essential for safe, effective weight loss treatment. Wegovy (semaglutide) follows a carefully designed five-step dose escalation over 16 weeks, gradually increasing from 0.25mg to the 2.4mg maintenance dose to minimise gastrointestinal side effects whilst maximising weight loss outcomes [1].

The Complete Wegovy Dosing Schedule UK Protocol

Wegovy follows a structured dose escalation designed by Novo Nordisk and approved by the MHRA for use in the UK. The schedule begins at 0.25mg once weekly for four weeks, then increases every four weeks through 0.5mg, 1.0mg, and 1.7mg doses before reaching the 2.4mg maintenance dose at week 17 [1].

This gradual titration is not arbitrary—clinical trials demonstrated that slow dose escalation significantly reduces the incidence and severity of nausea, vomiting, and diarrhoea compared to faster titration schedules [2]. In the STEP 1 trial, patients following this exact protocol achieved an average 14.9% body weight reduction over 68 weeks [2].

Each dose must be administered once weekly on the same day each week, with or without food. The injection can be given at any time of day, but consistency helps establish routine adherence, which directly correlates with treatment success [1].

Month-by-Month Wegovy Dose Escalation

Month 1 (Weeks 1-4): 0.25mg weekly. This introductory dose allows your body to adjust to semaglutide's effects on gastric emptying and appetite regulation. Most patients experience minimal side effects at this dose.

Month 2 (Weeks 5-8): 0.5mg weekly. Appetite suppression becomes more noticeable, and initial weight loss typically begins during this phase.

Month 3 (Weeks 9-12): 1.0mg weekly. Patients often report significant reduction in food cravings and portion sizes. Weight loss accelerates during this period.

Month 4 (Weeks 13-16): 1.7mg weekly. The penultimate dose before maintenance, where metabolic effects plateau and side effects should be minimal if previous doses were well-tolerated.

Month 5 onwards (Week 17+): 2.4mg weekly maintenance dose. This is the therapeutic dose used in all major STEP clinical trials and should be continued long-term for sustained weight management [2].

What Happens If You Miss a Wegovy Dose

If you miss your scheduled Wegovy injection and it has been fewer than five days since your missed dose, administer it as soon as you remember. Then resume your regular weekly schedule [3].

If more than five days have passed since your missed dose, skip that injection entirely and administer your next dose on your regularly scheduled day. Do not double up or take extra doses to compensate—this increases the risk of severe gastrointestinal side effects without improving efficacy [3].

Missing multiple consecutive doses may require restarting the dose escalation schedule from a lower dose, as determined by your UK prescriber. Extended gaps in treatment can increase side effects when resuming at higher doses [1].

Managing Side Effects During Wegovy Dose Escalation

Gastrointestinal side effects—primarily nausea, vomiting, diarrhoea, and constipation—are most common during the first 8-12 weeks of treatment as doses increase. In the STEP trials, these effects were generally mild to moderate and decreased over time as patients adapted to each dose level [2].

If side effects become intolerable at any dose level, your UK prescriber may recommend staying at your current dose for an additional 4 weeks before escalating, or in some cases, reducing back to the previous well-tolerated dose. Clinical experience shows that slower individualised titration improves long-term adherence without significantly compromising weight loss outcomes [4].

Practical strategies to minimise side effects include eating smaller, more frequent meals, avoiding high-fat foods, staying well-hydrated, and administering your injection in the evening so peak effects occur during sleep. These behavioural modifications, combined with the gradual dosing schedule, help most patients reach the full 2.4mg maintenance dose successfully [4].

When to Contact Your Prescriber

Seek immediate medical advice if you experience severe persistent abdominal pain (which may indicate pancreatitis), visual changes, signs of thyroid nodules, or symptoms of severe dehydration such as dizziness, reduced urination, or rapid heartbeat [3].

Contact your prescriber before your next scheduled dose increase if you experience persistent vomiting lasting more than 24 hours, are unable to keep down fluids, or if gastrointestinal symptoms are significantly impacting your daily activities. Dose adjustments may be necessary to ensure safe, tolerable treatment [3].

Wegovy Injection Technique and Administration Sites

Wegovy is administered subcutaneously (under the skin) using a pre-filled single-dose pen. The three approved injection sites are the abdomen (at least 5cm away from the navel), the front of the thigh, or the upper arm. Rotating injection sites each week helps prevent lipodystrophy and injection site reactions [1].

The pen is designed for ease of use: attach a new needle, dial to the prescribed dose (which is pre-set in dose-specific pens), insert the needle at a 90-degree angle into pinched skin, press the dose button until it clicks, and hold for 6 seconds before withdrawing. The pen window will show a green checkmark when the full dose has been delivered [3].

Store unused Wegovy pens in the refrigerator at 2-8°C. Once in use, pens can be kept at room temperature (below 30°C) for up to 28 days. Never freeze Wegovy, and discard any pen that has been frozen. Each pen is single-use only and should be disposed of in a sharps container after administration [3].

Clinical Evidence Behind the Wegovy Dosing Schedule

The 16-week dose escalation protocol used for Wegovy was established through the STEP clinical trial programme, which enrolled over 4,500 adults with obesity or overweight with weight-related comorbidities across five major studies [2].

STEP 1, the largest trial, demonstrated that 68 weeks of treatment with the 2.4mg maintenance dose (following the standard escalation schedule) resulted in mean weight loss of 14.9% compared to 2.4% with placebo. Critically, 86.4% of participants on the escalation protocol completed the full trial, indicating excellent tolerability when doses are increased gradually [2].

Subsequent analysis showed that patients who reached and maintained the 2.4mg dose experienced significantly greater improvements in cardiovascular risk markers, including blood pressure, lipid profiles, and HbA1c levels, compared to those who remained on lower doses due to intolerance [5]. This evidence supports the importance of following the complete dosing schedule to achieve optimal therapeutic outcomes.

Long-Term Maintenance Dosing

Once the 2.4mg maintenance dose is reached at week 17, it should be continued indefinitely for sustained weight management. Clinical data shows that discontinuing Wegovy typically results in gradual weight regain, with patients regaining approximately two-thirds of lost weight within one year of stopping treatment [5].

Long-term safety data from extension studies following patients for up to 104 weeks on the 2.4mg maintenance dose showed no new safety signals and sustained weight loss maintenance, supporting the use of Wegovy as a chronic weight management therapy rather than a short-term intervention [5].

Getting Started with Wegovy at Cured Pharmacy

At Cured Pharmacy, Wegovy is available from £79.00 with a free online consultation completed in under three minutes. Our UK-registered prescribers, overseen by Superintendent Pharmacist Tarun Kumar (GPhC 2233073), assess your medical history, current medications, and weight loss goals to determine if Wegovy is appropriate for your individual circumstances.

All Wegovy supplied through Cured Pharmacy is genuine UK-licensed medication sourced directly from authorised wholesalers and dispensed in accordance with MHRA and GPhC regulations. Your prescription will be dispensed with clear dosing instructions matching the standard escalation schedule, along with comprehensive patient information materials.

Delivery is 100% discreet with no pharmacy branding on external packaging. Once your prescription is approved, your first month's supply (four 0.25mg pens) is dispatched for next-day delivery across the UK. Ongoing monthly prescriptions can be arranged to ensure you progress through the dose escalation schedule without interruption, subject to continued prescriber approval at each stage.

Scientific References

1. European Medicines Agency. (2021). Wegovy (semaglutide): Summary of Product Characteristics. EMA/CHMP. [accessed 13 August 2026]
2. Wilding, J. P. H., et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
3. Novo Nordisk. (2023). Wegovy 2.4mg Solution for Injection in Pre-filled Pen: Patient Information Leaflet. Medicines and Healthcare products Regulatory Agency. [accessed 13 August 2026]
4. Rubino, D., et al. (2021). Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA, 325(14), 1414–1425. https://doi.org/10.1001/jama.2021.3224 [accessed 13 August 2026]
5. Garvey, W. T., et al. (2022). Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine, 28(10), 2083–2091. https://doi.org/10.1038/s41591-022-02026-4 [accessed 13 August 2026]
6. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
7. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
8. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication.